The EBNA564–583 20-mer peptide has been used in analyzing specific CD4+ T cell response in HLA-DP5+ EBV-seropositive healthy donors (24) and for vaccinating EBV-associated NPC patients (56). Here, CD4 is linked to nasopharyngeal carcinoma.